



an Open Access Journal by MDPI

## Interferons 2015

Guest Editor:

### **Dr. Howard A. Young**

Principal Investigator & Deputy  
Lab Chief, Laboratory of  
Experimental Immunology,  
Cancer and Inflammation  
Program, Center for Cancer  
Research, National Cancer  
Institute at Frederick, Bldg.  
560/31-23, Chandler Street,  
Frederick, MD 21702-1201, USA

Deadline for manuscript  
submissions:

**closed (30 June 2015)**

### **Message from the Guest Editor**

Dear Colleagues

The journal *Pharmaceuticals* will be publishing a Special Issue covering the topic, “Interferons”, and I cordially invite you to contribute an article to this volume.

Since their discovery over 50 years ago, interferons have impacted cancer research, autoimmunity, and host responses to infection. Also, a huge commercial market has developed for interferons because they became critical for treating hepatitis B and C. However, the use of interferons is changing. This Special Issue will highlight recent developments in the clinical use of these drugs (including Type I, II, and III interferons). In addition, we welcome the presentation and discussion of new preclinical models for interferons in order to offer participants a vision into the future of interferons in the clinic.

Dr. Howard A. Young

*Guest Editor*



[mdpi.com/si/3846](http://mdpi.com/si/3846)

# Special Issue



an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Ciências, Universidade de Lisboa, Lisboa, Portugal

## Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*.

*Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals* soon.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

**Journal Rank:** JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

## Contact Us

*Pharmaceuticals* Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/pharmaceuticals](http://mdpi.com/journal/pharmaceuticals)  
[pharmaceuticals@mdpi.com](mailto:pharmaceuticals@mdpi.com)  
[X@Pharmaceut\\_MDPI](https://twitter.com/Pharmaceut_MDPI)